Call for Abstracts Deadline: February 10, 2014

The 2014 International Conference on Nanoscience + Technology (ICN+T) will provide an international forum for discussion of the latest developments in nanoscale science and technology and recent advances in scanning probe microscopy and related techniques. The ICN+T represents the convergence of the former International Conference on Scanning Tunneling Microscopy/Spectroscopy and Related Techniques (STM) and Nano, which were first combined in Basel, Switzerland in 2006. This conference will cover a range of topics in nanoscale science and technology, addressing the interdisciplinary, international nature of this exciting and rapidly growing field.

[button size=”medium” align=”center” link=”” color=”white” hoverTextColor=”#0056E7″]Go to the website[/button]

The British Society for Nanomedicine (BSNM) is proud to collaborate with SELECTBIO in the organisation of Nanomedicine 2014. BSNM is a registered charity, created to allow open access for industry, academia, clinicians and the public to news and details of on-going nanomedicine research throughout the UK and beyond. A key aim of BSNM is the provision of forums for scientists to disseminate their latest advances and highlight their work to the wider scientific community. The exciting Nanomedicine 2014 programme will provide insight across a number of emerging nanotechnologies that span from treatment to diagnosis. The programme includes the use of solid drug nanosuspensions for improving oral bioavailability and for sustained release formulations, recent developments in targeting nanoparticles through the use of aptamers conjugated to their surface and progress in siRNA delivery as well as cell and particle imaging. The Conference Chair is Dr Andrew Owen, Professor of Pharmacology and Chair of the British Society for Nanomedicine, University of Liverpool.

Attending this event will provide you with excellent opportunities for networking with like minded peers, helping you to find solutions and build collaborations.

[button align=”left” link=”″ linkTarget=”_self” color=”blue” width=”81″]Register[/button]


Check out our 2for1 offer!

Oslo, 6 September 2013 – Thin Film Electronics ASA (“Thinfilm” (OSE: THIN.OL) announced today that funds managed by Invesco Asset Management Limited (“Invesco” have agreed to acquire 56,000,000 shares in the Company at a subscription price of NOK 2.50 per share totalling NOK 140,000,000 (USD 23 million). Following EGM approval, Invesco will hold 13.3% of the shares in the Company.

Upon subscription in the offering, Invesco will also receive 46,666,666 warrants, each with an exercise price of NOK 3.00. The warrants are exercisable after a 12-month holding period, and expire in 3 years.

The issuance of shares and warrants are subject to the approval of an extraordinary general meeting in Thinfilm. An EGM will be called for as soon as practical and will take place on or about 2 October 2013. A listing prospectus will be prepared in connection with the placement.

“Having Invesco, a global blue chip investor, acquire a significant interest in the company is a reflection of our increasing international presence. It is also a recognition of the importance of our Memory Everywhere vision for the emerging Internet of Everything. Our brand protection and smart label products are expected to have an impact on broad vertical markets, such as consumer packaged goods, health care, and retail. This investment provides capital to accelerate our ambitious roadmap”, said Davor Sutija, CEO of Thinfilm.


Thin Film Electronics ASA (Ticker: THIN.OL) is a leader in the development of Printed Electronics. The first to commercialize printed rewritable memory, Thinfilm is creating printed system products that will include memory, sensing, display and wireless communication—at a cost-per-functionality unmatched by any other electronic technology. Thinfilm’s roadmap of system products integrates technology from a strong and growing ecosystem of partners to enable the Internet of Things by bringing intelligence to disposable goods. Company headquarters are in Oslo, Norway, with product development in Linköping, Sweden, sales offices in San Francisco, USA, and Tokyo, Japan, and manufacturing in Pyongtaek, South Korea.

Follow us on Twitter:
Follow us on LinkedIn:

For more information, please contact:

Thin Film Electronics ASA
Heidi Arnesen
Communications Manager
+47 95 93 73 99


Gambit Hill + Knowlton Strategies
Knut Ekern
T +4722048200
M +47 93002600

This is the second phase survey of NANOMED 2020, dedicated to the analysis and optimization of the nanomedicine value chain and development process,

This survey has been designed to give complementary information to a previous work on establishing the nanomed milestones, with the objectives to:
·        identify the main barriers and needs along each step of the value chain, from idea and research all the way to market and commercialisation.

·        assess the interplay between the different stakeholders involved and the main differences of perspectives at the key interfaces

·        provide all participants with the possibility to comment and endorse the milestones and checklists established so far by the NanoMed2020 consortium

Go to the survey:

The aim of this survey is to gather key insights into the nanomedicine development process in order to identify the main barriers and needs along each step of the value chain, from idea and research all the way to market and commercialisation.

Focusing on each relevant category of stakeholder, the data will provide a major opportunity to assess the interplay between the different stakeholders involved and the main differences of perspectives at the key interfaces.

Finally, this survey will provide all participants with the possibility to comment and endorse the milestones and checklists established so far by the NanoMed2020 consortium to ensure successful development and uptake from idea to product on the market.

About NanoMed 2020:The NANOMED2020 Coordination and Support Action under the FP7-Health started in September 2012 for a duration of 18 months and aims at federating the nanomedicine community in Europe and delivering concrete recommendations to the European Commission to push forward the field of nanomedicine under Horizon 2020.

Save the date – Oct.1st-2nd! ETPN Annual Event and General Assembly 2013

The 1st Nanomedicine Award aims to reward European projects that have developed innovative solutions based on nanomedicine that can ultimately change the way diseases are treated or diagnosed and that could provide new tools for physicians and large benefits to patients.

Open to companies, academic and private researchers from European and non-European countries, the Nanomedicine Award aims to honor the best international nanomedicine innovations. Proposals will be evaluated in two areas: Concept/preclinical Award and a Clinical Award for application in nanotherapeutics or regenerative medicine.

Call for Proposals opens June 6, 2013 and ends September 7, 2013. Please click the link below.


is an annual investor-, partner- and network- meeting for international delegates. In 2013 SwedenBIO is proud host for the meeting, for the first time in collaboration with our sister organizations in Denmark, Finland and Norway.

Join us in Stockholm on Oct 14-15!

The event has a page on its own. Please see updates at

banner_lifescience 2013_2

The Lab-on-a-Chip World Congress will bring together leaders from both academia and industry to discuss innovative developments in this exciting field, with presentations exploring the latest advances in microfluidics and microfabrication. Attention will also be given to some of the many applications of Labs-on-Chips, from the enhancement of life science research, to taking diagnostics to the point of need.

Registration: 2for1 Offer!


This International Congress & Exhibition is designed to take stock of the latest developments in Nanobiotechnology bringing together academics, engineers and clinical specialists from public and private institutions across many disciplines to share their discoveries and innovations.

Registration now fully opened!
Discounted early registration rates deadline: Until May, 15th!
Visit this page to know more:

Answer a questionnaire on nanomedicine in Europe!
This survey is part of the EU project NanoMed. The purpose is to evaluate and provide concrete suggestions regarding the nanomedicine field in Horizon 2020. With the aim to more effectively identify and provide recommendations for the commercialization of nanomedicine products.


The survey takes about 10 minutes to complete, and everyone participating in the survey will be able to take part of the result.

NMN has initiated a contact with ETPN to discuss a closer collaboration. The ETPN is an initiative led by industry and set up together with the European Commission since 2006 in order to promote and support Nanomedicine,
A key task of this platform and of a CSA project named Nanomed2020 is the identification and federation of the Nanomedicine community in Europe and worldwide.